Journal of Pharmacology and Pharmacotherapeutics, Ahead of Print.
BackgroundDoxorubicin (DOX), an anthracycline-based chemotherapeutic agent, has been widely used as a first-line treatment for several cancers, including hematological and solid tumors, but its clinical utility is limited by severe cardiotoxicity and …